Business
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021
The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST CORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"The Company will host a Conference Call and Webcast on November 10, 2021, at 8:30 AM EST\nCORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021. Catalyst's management team will host a conference call and webcast the following morning, Wednesday, November 10, 2021, at 8:30 AM EST to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time: November 10, 2021, at 8:30 AM ESTUS/Canada Dial-in Number:(877) 407-8912International Dial- in Number:(201) 689-8059 A webcast and accompanying materials will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A replay of the webcast will be available on the Catalyst website for 30 days following the date of the event. About Catalyst PharmaceuticalsCatalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration (\"FDA\"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. FIRDAPSE is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis. Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to ...